Sanofi - ADR
SNY
Market Cap$122.04B
Close$
Earnings Call Q2 2025
July 31, 2025 - AI Summary
Strong Q2 Performance: Sanofi reported a net sales increase of 10.1% at constant exchange rates for Q2 2025, driven by their new launches, vaccines, and Dupixent. Dupixent alone generated sales of EUR 3.8 billion, reflecting a 21% increase year-over-year, with strong growth across various indications and markets.
Revised Sales Guidance: The company has refined its 2025 sales guidance to high single-digit percentage growth at constant exchange rates, indicating increased confidence in business performance due to strong demand for growth drivers like Dupixent and new product launches.
Launches and Acquisitions: Q2 2025 saw close to EUR 1 billion generated from nine new product launches, marking 10% of total sales and demonstrating effective execution in bringing innovative treatments to market. The completion of the Blueprint Medicines acquisition bolstered Sanofi's presence in rare immunology diseases, with Ayvakit achieving USD 175 million in sales in Q2.
Exclusive for Stockcircle Pro members
Sign up
$55.22
21.8% upside
Current Fair Value
21.8% upsideUndervalued by 21.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $122.04 Billion |
|---|---|
| Enterprise Value | $129.69 Billion |
| Dividend Yield | $2.21 (4.64%) |
| Earnings per Share | $2.3 |
| Beta | 0.41 |
| Outstanding Shares | 2,467,800,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.35 |
|---|---|
| PEG | 15.04 |
| Price to Sales | 2.67 |
| Price to Book Ratio | 1.62 |
| Enterprise Value to Revenue | 3.01 |
| Enterprise Value to EBIT | 16.2 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.33 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sanofi
CEO: Paul Hudson Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...